Stimson Ella, Shea Delaney, Gomes Michelle M, Ranganathan Srivathsan, Mitchell Sarah, Ware Jason, Armstrong Randall, Ross Christian, Heller Michael, Ibsen Stuart D
Cancer Early Detection Advanced Research Center, Knight Cancer Institute, Oregon Health & Science University, Portland, OR, 97201, USA.
Department of Biomedical Engineering, School of Medicine, Oregon Health & Science University, Portland, OR, 97201, USA.
Small. 2025 Jun;21(24):e2404457. doi: 10.1002/smll.202404457. Epub 2025 Mar 26.
Protease activity is an emerging biomarker for cancer detection as activity levels are often increased in tumor tissue compared to healthy tissue. Of particular interest is the activity of proteases carried by extracellular vesicle (EV) nanoparticles which are oversecreted by tumors into circulation. Current methods to analyze the activity of proteases bound to EVs require complex multi-instrument sample processing to separate EVs from plasma to quantify protease activity. This makes EV-based protease activity detection a challenge for diagnostic or point-of-care applications. Here, a method is reported that manipulates EV nanoparticles and charged molecular byproducts from protease activity using two different electrokinetic phenomena generated by a single electrode microarray within a microfluidic channel. Dielectrophoresis is first generated to recover EVs carrying active trypsin-like proteases from human plasma followed by electrophoresis for subsequent analysis of peptide cleavage products indicating protease activity. This method demonstrates signal amplification through protease catalytic activity in combination with concentrating mechanisms of dielectrophoresis and electrophoresis. Using this approach, a significant difference in protease activity is observed between patients with pancreatic cancer and benign cysts. This demonstrates dual-electrokinetic chip-based technology as a useful tool to manipulate different sized and charged analytes in a single device enabling future clinical translation of EV-based protease diagnostics.
蛋白酶活性作为一种新兴的癌症检测生物标志物,因为与健康组织相比,肿瘤组织中的活性水平通常会升高。特别令人感兴趣的是细胞外囊泡(EV)纳米颗粒携带的蛋白酶的活性,这些纳米颗粒由肿瘤过度分泌到循环系统中。目前分析与EV结合的蛋白酶活性的方法需要复杂的多仪器样本处理,以从血浆中分离出EV来量化蛋白酶活性。这使得基于EV的蛋白酶活性检测对于诊断或即时检测应用来说是一项挑战。在此,报道了一种方法,该方法利用微流控通道内的单个电极微阵列产生的两种不同的电动现象来操纵EV纳米颗粒和蛋白酶活性产生的带电分子副产物。首先产生介电泳以从人血浆中回收携带活性胰蛋白酶样蛋白酶的EV,然后进行电泳以随后分析表明蛋白酶活性的肽裂解产物。该方法通过蛋白酶催化活性结合介电泳和电泳的浓缩机制证明了信号放大。使用这种方法,在胰腺癌患者和良性囊肿患者之间观察到蛋白酶活性存在显著差异。这证明了基于双电动芯片的技术是一种在单个设备中操纵不同大小和带电分析物的有用工具,有望实现基于EV的蛋白酶诊断的未来临床转化。